CTRI/2025/12/098345Not yet recruitingNot Applicable
Cell free DNA as markers of malignancy in thyroid nodules
Dr Smita Sonoli1 site in 1 country200 target enrollmentStarted: December 13, 2025Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- To detect thyroid malignancies at an early stage, improving treatment outcomes and patient survival rates
Study Overview
Brief Summary
Introduction Thyroid malignancy is the most common endocrine malignancy which usually presents as a solitary thyroid nodule. Studies have suggested that 5 percent to 15 percent of all thyroid nodules evaluated are malignant. We propose to differentiate malignant from benign thyroid nodules by quantification of plasma cell free DNA.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18.00 Year(s) to 80.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Consecutive patients attending the endocrinology OPD.
Exclusion Criteria
- •Hyperthyroidism with multi nodular disease on ultrasonography.
- •Anaplastic cancer and medullary thyroid cancer.
- •Patients with past/current history of any known malignancies.
Outcomes
Primary Outcomes
To detect thyroid malignancies at an early stage, improving treatment outcomes and patient survival rates
Time Frame: 8 weeks
Secondary Outcomes
No secondary outcomes reported
Investigators
Dr Smita Sonoli
KAHER Jawaharlal Nehru Medical College
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial CancerNCT07270666Memorial Sloan Kettering Cancer Center30
Not yet recruiting
Not Applicable
Testing blood markers to check gum health in smokers and non-smokers.CTRI/2025/08/093243Dr Sruthy Sudir60
Recruiting
Not Applicable
Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood SamplingNCT07310537Erasmus Medical Center35
Not yet recruiting
Not Applicable
Detecting Rare Cancer Cells and DNA in blood samples of Early-Stage Triple-Negative Breast Cancer After ChemotherapyCTRI/2024/12/078366OneCell Diagnostics50
Not yet recruiting
Not Applicable
Clinical Utility of ctDNA in the Treatment of Oligometastatic DiseaseNCT07426250Aarhus University Hospital500